Decision: Favourable

Decisions Table

Study Title:

A Randomized, Multicenter, Phase 3 Study of Zanidatamab in Combination with Chemotherapy with or without Tislelizumab in Subjects with HER2-positive Unresectable

  • NREC Code:

    22-NREC-CT-013

  • Decision:

    Favourable

  • Meeting Date:

    26/01/2022

  • Study Type:

    CT application

  • Principal Investigator:

    Professor Maeve Lowery

  • PI Institution:

    St. James's Hospital, Dublin

  • Sponsor:

    Zymeworks Inc. / PPD

Scroll to Top